Myriad Genetics Files 8-K

Ticker: MYGN · Form: 8-K · Filed: Jun 3, 2024 · CIK: 899923

Myriad Genetics Inc 8-K Filing Summary
FieldDetail
CompanyMyriad Genetics Inc (MYGN)
Form Type8-K
Filed DateJun 3, 2024
Risk Levellow
Pages3
Reading Time3 min
Key Dollar Amounts$0.01, $950,000
Sentimentneutral

Sentiment: neutral

Topics: disclosure, financials

Related Tickers: MYGN

TL;DR

MYGN filed an 8-K, standard financial/reg disclosure, no new news.

AI Summary

Myriad Genetics, Inc. filed an 8-K on June 3, 2024, to report on Regulation FD Disclosure and Financial Statements and Exhibits. The filing does not contain specific financial figures or material events beyond the standard reporting requirements for these sections.

Why It Matters

This 8-K filing serves as a routine disclosure for Myriad Genetics, Inc., indicating updates related to financial statements and regulatory disclosures without announcing new material events.

Risk Assessment

Risk Level: low — The filing is a routine 8-K for financial statements and exhibits, not indicating any new material risks or events.

Key Players & Entities

  • MYRIAD GENETICS INC (company) — Registrant
  • June 3, 2024 (date) — Date of earliest event reported
  • Delaware (jurisdiction) — State of incorporation
  • 801-584-3600 (phone_number) — Registrant's telephone number

FAQ

What is the primary purpose of this 8-K filing for Myriad Genetics, Inc.?

The primary purpose of this 8-K filing is to report on Regulation FD Disclosure and Financial Statements and Exhibits.

On what date was the earliest event reported in this filing?

The earliest event reported in this filing was on June 3, 2024.

In which state is Myriad Genetics, Inc. incorporated?

Myriad Genetics, Inc. is incorporated in Delaware.

What is the principal executive office address for Myriad Genetics, Inc.?

The principal executive office address is 322 North 2200 West, Salt Lake City, Utah 84116.

Does this 8-K filing announce any specific new material events or financial results?

This 8-K filing does not specify any new material events or financial results beyond the standard reporting categories of Regulation FD Disclosure and Financial Statements and Exhibits.

Filing Stats: 865 words · 3 min read · ~3 pages · Grade level 11.6 · Accepted 2024-06-03 16:06:29

Key Financial Figures

  • $0.01 — ange on which registered Common Stock, $0.01 par value MYGN Nasdaq Global Select Mar
  • $950,000 — and expenses in an amount not to exceed $950,000 to be paid by the Company and that the

Filing Documents

01 Regulation FD Disclosure

ITEM 7.01 Regulation FD Disclosure. Beginning on August 9, 2021, two purported shareholder derivative complaints were filed with the Court of Chancery of the State of Delaware (the " Court ") against Myriad Genetics, Inc. (the " Company "), as nominal defendant, and certain of the Company's current and/or former directors and officers. On March 3, 2022, the cases were consolidated under the caption In re Myriad Genetics, Inc. Stockholder Derivative Litigation , Case No. 2021-0686-SG (the " Derivative Action "). During the same period, a purported stockholder derivative complaint against the Company and certain current and/or former directors and officers of the Company was filed with the United States District Court for the District of Delaware, captioned Marcey v. Capone, et al. , Case No. 1:21-cv-01320-MN (D. Del.) (the " Federal Derivative Action ", and together with the Derivative Action, the " Derivative Litigation "). The complaints generally allege that certain current and former officers and/or directors of the Company breached their fiduciary duties to the Company and engaged in other wrongdoings. On April 30, 2024, the parties agreed to settle the Derivative Litigation pursuant to a global Stipulation of Settlement (the " Stipulation "). The Stipulation and the settlement contemplated therein (the " Proposed Settlement "), which is subject to the approval of the Court, are intended by the parties to fully, finally, and forever compromise, discharge, resolve, release, and settle the claims in the Derivative Litigation and to result in the complete dismissal of the Derivative Litigation with prejudice, upon the terms and subject to the conditions set forth in the Stipulation. The Proposed Settlement involves (i) the Company adopting or implementing certain corporate governance reforms and (ii) plaintiffs' counsel applying to the Court for an award of attorneys' fees and expenses in an amount not to exceed $950,000 to be paid by the Company and that the i

01 Financial Statements and Exhibits

ITEM 9.01 Financial Statements and Exhibits. Exhibit Number Description 99.1 Notice of Proposed Derivative Settlement 99.2 Stipulation of Settlement 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. MYRIAD GENETICS, INC. Date: June 3, 2024 By: /s/ Scott J. Leffler Scott J. Leffler Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.